Resource Center
Resource Center
Early testing of HIV-exposed infants and the initiation of antiretroviral therapy for HIV-positive infants is critical to improving infant survival. Learn about evidence from a Demand-Driven Evaluations for Decisions (3DE) Evaluation in Southern Province, Zambia that measured the impact of reinforced integration of infant HIV testing and immunization services here.
Read moreOn an autumn day in 2014 in the mountainous province of Yen Bai, Vietnam, an expectant mother, Yên, 27, was admitted to the Obstetric Department of Yen Bai Provincial General Hospital with pain she attributed to premature labor. “Yesterday she was still smiling and happily talking about her baby” said her mother, who accompanied her...
Read moreAccess to better tolerated, more convenient regimens for HIV treatment promotes adherence and leads to better patient outcomes. CHAI is working to ensure affordable pricing and to address demand-side barriers to access. Increased uptake of optimal second-line regimens in Uganda and Nigeria has improved HIV treatment and will deliver US$6.5 million in savings by 2018....
Read moreAchieving universal access to HIV treatment requires using the resources available as efficiently as possible. To this end, CHAI supports 10 countries to conduct annual resource mapping. In Malawi, results have informed the allocation of US$300 million to high-impact interventions and increased national ownership of the HIV response. Learn more about CHAI’s work improving efficiency...
Read moreCHAI and global partners in the Diagnostics Access Initiative have joined with Roche Diagnostics to announce a 35 percent reduction in the price for HIV early infant diagnostic technologies. The new access price is US$9.40 per test, including proprietary reagents and consumables associated with diagnosing HIV in very young children. Learn more here.
Read moreViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV London, May 26, 2015 – ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA)...
Read moreCHAI supports national governments to expand high-quality care and treatment to people living with HIV/AIDS.
Read moreHIV viral load testing improves the quality of care for patients on antiretroviral therapy. CHAI partnered with the Government of South Africa, UNAIDS, PEPFAR, Global Fund to Fight AIDS, Tuberculosis and Malaria, and Roche to negotiate a global access price for viral load of US$9.40 per test, which will save more than US$150 million between...
Read moreIn late July Vancouver hosted the 8th annual International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment & Prevention. Over 20 CHAI staff members from around the world presented a wide variety of work at the meeting. The conference was characterized by a few themes, among them a continued commitment to the ambitious “90-90-90” target:...
Read moreCHAI's ARV Market Report provides a global perspective on the ARV marketplace in low- and middle-income countries in 2013 and outlines CHAI's expectations on how this market will evolve over the next five years.
Read more